Floatz logo

[225Ac]Ac-AKY-1189

Triple Negative Breast Cancer (TNBC)

Aktis Oncology, Inc.radiopharmaceuticalPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

447 Active assets in the Triple Negative Breast Cancer (TNBC) cohort.

Asset / SponsorPhaseRating
Capivasertib
AstraZeneca
Phase 3BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Carboplatin
M.D. Anderson Cancer Center
Phase 4BB
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Atezolizumab
European Institute of Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

[225Ac]Ac-AKY-1189 is also rated in:

hormone receptor-positive breast cancerDormant
CC
Indicative ·
43 / 100
View asset →
cervical adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →